Header Logo

VIRGIL CRAIG JORDAN

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jordan VC. Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Res Treat. 2021 Nov; 190(1):19-38. PMID: 34398352; PMCID: PMC8557169.
      Citations: 2     Fields:    Translation:HumansAnimals
    2. Jordan VC. Serendipity in the search for "morning-after pills" led to clomiphene for the induction of ovulation. F S Sci. 2020 Aug; 1(1):3-13. PMID: 35559738.
      Citations:    
    3. Jordan VC. Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. Cancer Prev Res (Phila). 2020 10; 13(10):807-816. PMID: 32669317.
      Citations: 7     Fields:    Translation:Humans
    4. Jordan VC. ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery. Ann Surg Oncol. 2019 Jul; 26(7):1991-1992. PMID: 30997629.
      Citations:    Fields:    Translation:Humans
    5. Jordan VC. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Ann Surg Oncol. 2019 Jul; 26(7):1981-1990. PMID: 30911948; PMCID: PMC6545250.
      Citations: 6     Fields:    Translation:Humans
    6. Jordan VC. Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clin Cancer Res. 2018 08 01; 24(15):3480-3482. PMID: 29674510; PMCID: PMC6082682.
      Citations: 4     Fields:    Translation:Humans
    7. Jordan VC. The Study of Letrozole Extension (SOLE) revisited. Lancet Oncol. 2018 02; 19(2):e77. PMID: 29413478.
      Citations: 1     Fields:    Translation:Humans
    8. Jordan VC. The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice. Cancer Prev Res (Phila). 2017 Apr; 10(4):219-222. PMID: 28246081; PMCID: PMC5779859.
      Citations: 2     Fields:    Translation:Humans
    9. Jordan VC. A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications. Integr Cancer Ther. 2016 09; 15(3):242-4. PMID: 27271771; PMCID: PMC5739192.
      Citations: 1     Fields:    Translation:Humans
    10. Jordan VC. A Retrospective: On Clinical Studies with 5-Fluorouracil. Cancer Res. 2016 Feb 15; 76(4):767-8. PMID: 26880809.
      Citations: 4     Fields:    Translation:Humans
    11. Jordan VC, Curpan R, Maximov PY. Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. J Natl Cancer Inst. 2015 Jun; 107(6):djv075. PMID: 25838462; PMCID: PMC6390275.
      Citations: 16     Fields:    Translation:Humans
    12. Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015 Feb; 22(1):R1-31. PMID: 25339261; PMCID: PMC4494663.
      Citations: 64     Fields:    Translation:HumansAnimals
    13. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE, International Tamoxifen Pharmacogenomics Consortium, Dieudonn? AS, Wegman P, Wingren S. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014 Feb; 95(2):216-27. PMID: 24060820; PMCID: PMC3904554.
      Citations: 64     Fields:    Translation:Humans
    14. Baniwal SK, Chimge NO, Jordan VC, Tripathy D, Frenkel B. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. PLoS One. 2014; 8(6):e62361. PMID: 23755096; PMCID: PMC3670933.
      Citations: 17     Fields:    Translation:HumansCells
    15. Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 04; 32(27):3274-85. PMID: 22907432; PMCID: PMC3505272.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    16. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project, Robidoux A. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010 Jun; 3(6):696-706. PMID: 20404000; PMCID: PMC2935331.
      Citations: 198     Fields:    Translation:Humans
    17. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2635-40. PMID: 19202070; PMCID: PMC2637277.
      Citations: 85     Fields:    Translation:Animals
    18. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007 Dec 20; 25(36):5815-24. PMID: 17893378.
      Citations: 130     Fields:    Translation:Humans
    19. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006 Dec; 58(4):773-81. PMID: 17132854.
      Citations: 159     Fields:    Translation:HumansAnimals
    20. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      Citations: 88     Fields:    Translation:HumansCells
    21. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP), Robidoux A. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21; 295(23):2727-41. PMID: 16754727.
      Citations: 456     Fields:    Translation:Humans
    22. Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL, Gartenhaus RB. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res. 2005 Dec 01; 65(23):10651-6. PMID: 16322206.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    23. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther. 2004 May; 3(5):460-7. PMID: 15020841.
      Citations: 11     Fields:    Translation:HumansCells
    24. Mishra SK, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan VC, Santen RJ, Kumar R. MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem. 2003 May 23; 278(21):19209-19. PMID: 12639951.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    25. Chatterton RT, Lydon JP, Mehta RG, Mateo ET, Pletz A, Jordan VC. Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett. 2002 Dec 15; 188(1-2):47-52. PMID: 12406547.
      Citations: 10     Fields:    Translation:Animals
    26. Li D, Dragan Y, Jordan VC, Wang M, Pitot HC. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 1997 Apr 15; 57(8):1438-41. PMID: 9108442.
      Citations: 9     Fields:    Translation:Animals
    27. Buzdar AU, Hortobagyi GN. Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'. Breast Cancer Res Treat. 1985; 6(2):149-50. PMID: 4052642.
      Citations:    Fields:    Translation:Humans
    28. Estrogen receptor pathways and breast cancer. 189-206.
    29. Relevance of metabolic activation for the antihormone activity of tamoxifen. Cancer Treatment Reports. 63.
    30. Oestrogens, oestrogen receptors and breast cancer. European Journal of Cancer, Supplement. 1:1-12.
    31. Comparison of the effects of tamoxifen and monohydroxytamoxifen in the rat uterus and mammary gland. Journal of Steroid Biochemistry. 9:840.
    32. Continuing outcomes relevant to evista. Breast Diseases. 16:183.
    33. Breast cancer prevention. Seminars in Breast Disease. 6:2-10.
    34. Tamoxifen for breast cancer prevention. Breast Journal. 4:407-408.
    35. Questions about tamoxifen and the future use of antiestrogens. Oncologist. 3:104-110.
    36. Re. Journal of the National Cancer Institute. 87:1805-1806.
    37. Is there a role for raloxifene and tamoxifen for the prevention of breast cancer?. 83-101.
    38. A Raloxifene Withdrawal Response. Integrative Cancer Therapies. 15:242-244.
    39. Binding affinity of the nonsteroidal antiestrogens tamoxifen and mono-hydroxytamoxifen for the estrogen receptor from chick liver nuclei. Clinical Research. 28.
    40. Effects of ICI 182,780 on tamoxifen-stimulated breast and endometrial cancer. Breast Cancer Research and Treatment. 69:255.
    41. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. Discovery medicine. 21:321-337.
    42. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Current Signal Transduction Therapy. 4:88-102.
    43. Comparative metabolism of tamoxifen in mice, rats, and chickens. Federation Proceedings. 43.
    44. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. Obstetrical and Gynecological Survey. 47:578-580.
    45. Integration of downstream signals of insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer cells. Molecular Cancer Research. 13:1367-1376.
    46. Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget. 7:71235-71254.
    47. Identification of an estrogenic metabolite of tamoxifen during high-dose therapy for breast cancer. Breast Cancer Research and Treatment. 1.
    48. Steroid hormone receptors and human breast cancer. Laboratory Medicine. 16:287-294.
    50. In postmenopausal women with breast cancer, switching to exemestane increased disease-free survival compared to continuing tamoxifen. Evidence-based Obstetrics and Gynecology. 7:103-104.
    51. Guest editor's note. Breast Cancer Research and Treatment. 31:1-4.
    52. A personal account of the chemoprevention of breast cancer. 391-398.
    53. TAMOXIFEN AND ENDOMETRIAL CANCER. The Lancet. 333:733-734.
    54. The mode of action of the antitumour agent GP 48,989* * 5-Methyl-3-(2-methylallyl)-2-[(3-methyl-4-oxo-2-thiazolidinylidene)hydrazono]-4-thiazolidinone. in the rat. European Journal of Cancer (1965). 15:755-761.
    55. Differential antiestrogen action in the immature rat uterus. Journal of Steroid Biochemistry. 19:1241-1258.
    56. Improving long-term adjuvant anti-oestrogenic therapy for breast cancer. Clinical Pharmacist. 8.
    57. TAMOXIFEN AND ENDOMETRIAL CANCER. The Lancet. 332:1019.
    58. CHEMOTHERAPY. PROC. 9TH INT. CONGR. CHEMOTHER. VOLUME 7. CANCER CHEMOTHERAPY. 89-94.
    59. The modulation of estrogen-induced apoptosis as an interpretation of the womens health initiative trials. Expert Review of Endocrinology and Metabolism. 11:81-86.
    60. Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer. 5:99-106.
    61. Biology of SERMs and strategies for use. Obstetrical and Gynecological Survey. 53.
    62. Estrogen deprivation therapy in ovarian cancer. Journal of Clinical Oncology. 34:2675-2676.
    63. Changes in lipid metabolism by tamoxifen (multiple letters). International Journal of Clinical Oncology. 4:121-122.
    64. Cross-resistance of tamoxifen and raloxifene on the growth of raloxifene-resistant breast cancer cells in vivo and in vitro. Breast Cancer Research and Treatment. 69:255.
    65. Anti-estrogens and selective estrogen-receptor modulators. 884-892.
    66. Future directions in endocrine therapy for the treatment and prevention of breast cancer. Seminars in Breast Disease. 3:119-130.
    67. Role of estrogen receptor(ER)β in modulating ERα SERM complexes in MDA-MB-231 breast cancer cells. Breast Cancer Research and Treatment. 69:293.
    68. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. European Journal of Cancer. 50:457-468.
    69. Raloxifene stimulated endometrial cancer grown in athymic mice. Breast Cancer Research and Treatment. 69:288.
    70. Is over-expression of protein kinase C alpha required to induce a hormone-independent phenotype in T47D breast cancer cells?. Breast Cancer Research and Treatment. 69:276.
    71. Tamoxifen. 83-102.
    72. Chemoprevention breast cancer workshop, november 20, 1987 panel discussions. Cancer Investigation. 6:663-667.
    73. Assessing the safety of hormonal replacement therapy. Clinical Pharmacist. 8.
    74. Response to a letter from Anderson et al. Menopause. 19:836-837.
    75. The search for antiestrogens. Oncology (Switzerland). 22:682-684.
    76. Letter the editor (multiple letters). Breast Journal. 6:74.
    77. Oestrogen receptors, growth factors and the control of breast cancer. Breast. 10:27-35.
    78. IV.7 Tamoxifen and uterine cancer. European Journal of Cancer. 34.
    79. A realistic assessment of the association between tamoxifen and endometrial cancer. Endocrine-Related Cancer. 2:235-241.
    80. How long should adjuvant tamoxifen be continued? Commentary I. Oncology (Switzerland). 8.
    81. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Breast Diseases. 23:190-191.
    82. Raloxifene. 103-121.
    83. Targeted antiestrogens to prevent breast cancer. Trends in Endocrinology and Metabolism. 10:312-317.
    84. The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology.
    85. Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Obstetrical and Gynecological Survey. 48:690-691.
    86. ACCION DE ESTROGENOS Y ANTIESTROGENOS EN EL CANCER MAMARIO. Revista del Instituto Nacional de Cancerologia. 32:141-145.
    87. Tamoxifen may prove successful in long-term cancer prevention. American Family Physician. 43:1371.
    88. Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer. Geburtshilfe und Frauenheilkunde. 67:443-450.
    89. Evolution of estrogen action in breast cancer. 127-149.
    90. Health and safety at work - Developing the role of the health and safety executive. 173-176.
    91. Drug resistance to tamoxifen. Endocrine-Related Cancer. 2:45-51.
    92. Prevention of breast cancer. 63-94.
    93. V.3 Is there life after tamoxifen? New anti-oestrogens. European Journal of Cancer. 34.
    94. Update on tamoxifen, raloxifene, and breast cancer. IM - Internal Medicine. 20:8-19.
    95. Reversal of the Antitumor Effects of Tamoxifen by Progesterone in the 7,12-Dimethylbenzanthracene-induced Rat Mammary Carcinoma Model. Cancer Research. 47:5401-5406.
    96. Co-expression of ER and c-erb B2 in breast cancer. Breast Cancer Research and Treatment. 69:296.
    97. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer Part A. 32:1461-1463.
    98. Estrogen activity in plastic products. Environmental Health Perspectives. 119.
    99. Erratum. Expert Opinion on Pharmacotherapy. 13:1081.
    100. A STAR is born. Oncology (Switzerland). 20:1126.
    101. Corrigendum. Carcinogenesis. 17:1393.
    102. Characteristics of raloxifene-stimulated breast tumors in vivo. Breast Cancer Research and Treatment. 69:287.
    103. Editorial. Annals of Oncology. 3:595.
    104. Histopathology of rat mammary cancer and correlation with treatment response. 898.
    105. Laboratory models of hormone-dependent cancer. Clinics in Oncology. 1:21-40.
    JORDAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (171)
    Explore
    _
    Co-Authors (22)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _